Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Research and Innovation Action · Running

VICI-DISEASE Protection from Viruses with Epidemic and Pandemic Disease Outbreak Potential Through Development and Clinical Testing of a Novel Capsid Virus Like Particle (cvlp) Vaccine

Coordinator
Kobenhavns Universitet, Denmark
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
8 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101136281

What the project is doing

In the project's own words, from its summary on CORDIS.

The enormous health and economic impacts of epidemics and pandemics has become one of the defining public policy and health issues in Europe and throughout the world. A new urgency is required to understand, rapidly respond to, and vaccinate against viruses with epidemic and pandemic potential. The major challenge for the modern vaccines is the induction of long-term protective immunity, as clearly demonstrated by fast waning of protection for current COVID-19 vaccines.

VICI-DISEASE is an ambitious project which combines existing cutting-edge expertise in a tried and tested consortium, with new advances in this critical field. The consortium’s main objective is to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for further development (Phase 2&3) in case of pandemic outbreaks. The primary candidate will be Nipah virus (NiV), a high-mortality viral disease with no vaccines or treatments.

Our vaccine is based on NiV G protein displayed on capsid Virus Like Particle (cVLP), enabled by adapting template processes from our recent COVID-19 vaccine (currently in Phase 3), and expected to provide best-in-class longevity as shown for COVID-19.The VICI-DISEASE consortium’s objective is to develop and perform a clinical proof-of-concept study for •a highly effective (>90% protection),•long-term protective (>2 years),•NiV virus cVLP vaccine,•by adapting template processes established for our COVID-19 vaccine (currently in Phase 3),•within 48 months in a Phase 1/2a clinical study, •to help protect medical workers and the public from future NiV and Hendra virus outbreaks,•and establish a pipeline of novel filovirus vaccines through pre-clinical proof-of-concept studies.

We address the call topic by improving pandemic preparedness and response through development of a NiV vaccine to Ph1/2 and two filovirus vaccines to pre-clinical proof-of-concept.

Topics

Who is involved

OrganisationCityCountryRole
Kobenhavns UniversitetKobenhavnDenmarkCoordinator
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer TiergesundheitGreifswald-Insel RiemsGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Adaptvac ApsHorsholmDenmarkParticipant
Expres2ion Biotechnologies ApsHorsholmDenmarkParticipant
Centre de Recherches Medicales de LambarénéLambarénéGAAssociatedpartner
Psg Govindaswamy Naidu & Sons CharitieCoimbatoreIndiaAssociatedpartner
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI